Glucocorticoid-induced osteoporosis: an update on current pharmacotherapy and future directions

Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database

(2012) Volker Ziller et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Incidence of atypical nontraumatic diaphyseal fractures of the femur

(2012) Richard M Dell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effectiveness of Teriparatide in Postmenopausal Women with Osteoporosis and Glucocorticoid Use: 3-Year Results from the EFOS Study

(2012) D. KARRAS et al.   JOURNAL OF RHEUMATOLOGY

A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis

(2012) S. Lekamwasam et al.   OSTEOPOROSIS INTERNATIONAL

Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial

(2012) M Hakala et al.   SCANDINAVIAN JOURNAL OF RHEUMATOLOGY

Inflammatory Rheumatic Disorders and Bone

(2012) Irene E. M. Bultink et al.   Current Rheumatology Reports

Clinical Question: What is the best approach to managing glucocorticoid-induced osteoporosis?

(2011) Juliet Compston   CLINICAL ENDOCRINOLOGY

Glucocorticoid-Induced Bone Disease

(2011) Robert S. Weinstein   NEW ENGLAND JOURNAL OF MEDICINE

Advances in Glucocorticoid-Induced Osteoporosis

(2011) Debby den Uyl et al.   Current Rheumatology Reports

Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice

(2010) M. C. van der Goes et al.   ANNALS OF THE RHEUMATIC DISEASES

From bone biology to clinical outcome: state of the art and future perspectives

(2010) G. Schett et al.   ANNALS OF THE RHEUMATIC DISEASES

Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis?

(2010) Steven L. Teitelbaum et al.   ARTHRITIS AND RHEUMATISM

Silencing Dkk1 expression rescues dexamethasone-induced suppression of primary human osteoblast differentiation

(2010) Joseph S Butler et al.   BMC MUSCULOSKELETAL DISORDERS

Regulation of human bone marrow stromal cell proliferation and differentiation capacity by glucocorticoid receptor and AP-1 crosstalk

(2010) Iván Cárcamo-Orive et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research

(2010) Elizabeth Shane et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Oral bisphosphonate compliance and persistence: a matter of choice?

(2010) S. L. Silverman et al.   OSTEOPOROSIS INTERNATIONAL

Adherence and profile of non-persistence in patients treated for osteoporosis—a large-scale, long-term retrospective study in The Netherlands

(2010) J. C. Netelenbos et al.   OSTEOPOROSIS INTERNATIONAL

Compliance and persistence with osteoporosis medications: A critical review of the literature

(2010) Stuart Silverman et al.   REVIEWS IN ENDOCRINE & METABOLIC DISORDERS

American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis

(2010) Jennifer M. Grossman et al.   ARTHRITIS CARE & RESEARCH

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

(2009) R. K. Dore et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial

(2009) Kenneth G. Saag et al.   ARTHRITIS AND RHEUMATISM

Ibandronate Prevents Bone Loss and Reduces Vertebral Fracture Risk in Male Cardiac Transplant Patients: A Randomized Double-Blind, Placebo-Controlled Trial*

(2009) Astrid Fahrleitner-Pammer et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Once-Weekly Oral Alendronate 70 mg in Patients with Glucocorticoid-Induced Bone Loss: A 12-Month Randomized, Placebo-Controlled Clinical Trial

(2009) S. A. STOCH et al.   JOURNAL OF RHEUMATOLOGY

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

(2009) David M Reid et al.   LANCET

Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis

(2009) T. Beukelman et al.   OSTEOPOROSIS INTERNATIONAL

Preferences of GPs and Patients for Preventive Osteoporosis Drug Treatment

(2009) Esther W. de Bekker-Grob et al.   PHARMACOECONOMICS

How antirheumatic drugs protect joints from damage in rheumatoid arthritis

(2008) Georg Schett et al.   ARTHRITIS AND RHEUMATISM

Modulation of Dickkopf-1 Attenuates Glucocorticoid Induction of Osteoblast Apoptosis, Adipocytic Differentiation, and Bone Mass Loss

(2008) Feng-Sheng Wang et al.   ENDOCRINOLOGY

Glucocorticoid induces apoptosis of osteoblast cells through the activation of glycogen synthase kinase 3β

(2008) Sun-Il Yun et al.   JOURNAL OF BONE AND MINERAL METABOLISM

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL